Education
About Us
Working with TipRanks
Follow Us
Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
RXRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.60 - $12.36
Previous CloseN/A
Volume5.68M
Average Volume (3M)28.28M
Market Cap
$2.69B
Enterprise Value$1.52B
Total Cash (Recent Filing)$594.35M
Total Debt (Recent Filing)$108.49M
Price to Earnings (P/E)―
Beta3.54
Next Earnings
May 07, 2025EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding395,072,080
10 Day Avg. Volume16,859,275
30 Day Avg. Volume28,279,709
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)45.88
Price to Cash Flow (P/CF)-5.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit112.02
Enterprise Value/Ebitda-3.56
Forecast
1Y Price Target
$9.25Price Target Upside36.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company ended YE:24 with $603M in cash, providing runway into 2027.
Safety And EfficacyThe safety profile remains clean, with no SAEs related to drug and the majority of TEAEs Grade 1-2.
Strategic IntegrationRXRX is integrating EXAI’s precision chemistry platform with its operating system, which could provide strategic advantages.
Bears Say
Cash ManagementThe cash burn remains unsustainably high, putting pressure on deal execution and clinical development.
Clinical ValidationInvestors remain unconvinced of the platform validation as the two readouts last year failed to move the needle.
Financial PerformanceQ4 revenues of $4.5M missed expectations due to timing of projects related to the company's Roche/Genentech partnership.
---
Ownership Overview
3.98% Insiders
13.01% Mutual Funds
45.66% Other Institutional Investors
14.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RXRX FAQ
What was Recursion Pharmaceuticals’s price range in the past 12 months?
Recursion Pharmaceuticals lowest stock price was $5.60 and its highest was $12.36 in the past 12 months.
What is Recursion Pharmaceuticals’s market cap?
Recursion Pharmaceuticals’s market cap is $2.69B.
When is Recursion Pharmaceuticals’s upcoming earnings report date?
Recursion Pharmaceuticals’s upcoming earnings report date is May 07, 2025 which is in 43 days.
How were Recursion Pharmaceuticals’s earnings last quarter?
Recursion Pharmaceuticals released its earnings results on Feb 28, 2025. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.411 by -$0.119.
Is Recursion Pharmaceuticals overvalued?
According to Wall Street analysts Recursion Pharmaceuticals’s price is currently Undervalued.
Does Recursion Pharmaceuticals pay dividends?
Recursion Pharmaceuticals does not currently pay dividends.
What is Recursion Pharmaceuticals’s EPS estimate?
Recursion Pharmaceuticals’s EPS estimate is -0.52.
How many shares outstanding does Recursion Pharmaceuticals have?
Recursion Pharmaceuticals has 395,072,080 shares outstanding.
What happened to Recursion Pharmaceuticals’s price movement after its last earnings report?
Recursion Pharmaceuticals reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.411. Following the earnings report the stock price went down -2.086%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals?
Currently, no hedge funds are holding shares in RXRX
---
Recursion Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.25 (36.23% Upside)
$9.25 (36.23% Upside)
Blogger Sentiment
Bullish
RXRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 7.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.27%
12-Months-Change
Fundamentals
Return on Equity
-61.89%
Trailing 12-Months
Asset Growth
121.60%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
---
RXRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong year for Recursion with significant advancements in clinical programs, partnerships, and technology infrastructure. Financially, the company is well-positioned with a strong cash balance, despite some revenue recognition challenges. The overall sentiment is positive due to the substantial achievements outweighing the noted challenges.Read More>---
RXRX Stock 12 Month Forecast
Average Price Target
$9.25
▲(36.23% Upside)
Technical Analysis
Vertex Pharmaceuticals
―
Blueprint Medicines
―
Editas Medicine
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering RXRX
1 Year
---